By /

TB-500 Research Hub · Evidence Overview

TB-500 research evidence: what has actually been studied?

A careful review of TB-500 that separates the marketed fragment name from research on full-length thymosin beta-4.

JD BioWorks Research LibraryPublished: July 15, 2026Last reviewed: July 15, 2026Editorial review: JD BioWorks Research Library

Evidence at a glance

Human evidenceDirect controlled human evidence for the exact material commonly called TB-500 is not established. Human studies often cited in this area used full-length thymosin beta-4.
Preclinical evidenceFull-length thymosin beta-4 has a sizable cell, animal, ocular, wound, and early clinical literature. A fragment may not reproduce the parent peptide.
Evidence gapSequence definitions and naming are inconsistent, and evidence is frequently transferred from full-length thymosin beta-4 without justification.
ScopeTB-500 and full-length 43-amino-acid thymosin beta-4 must be treated as different test articles unless exact identity proves otherwise.
Interpretation note: Findings must stay tied to the exact molecule, formulation, model, population, and endpoint studied. A biological signal is not, by itself, proof of safety or effectiveness.

Overview

TB-500 is commonly described in commercial and sports contexts as a thymosin beta-4-related fragment, while many cited publications studied full-length 43-amino-acid thymosin beta-4 (Tβ4). Sequence, molecular weight, secondary structure, stability, and actin binding can differ. Therefore, this article separates direct TB-500 evidence from parent-peptide evidence.

Research background

Human research has evaluated recombinant or synthetic full-length Tβ4 in healthy volunteers, venous ulcers, and ophthalmic applications. Those studies establish that full-length Tβ4 has entered clinical research; they do not establish safety or efficacy for an unspecified fragment marketed as TB-500.

Findings by research area

Research area What has been reported What it does not establish
Exact TB-500 Direct, well-characterized controlled human studies are not established in the primary record reviewed here. Safety or efficacy in people.
Full-length Tβ4 Randomized healthy-volunteer and phase 2 topical studies have been published. Equivalent behavior of a fragment.
Preclinical Tβ4 Cell and animal work examines migration, actin biology, angiogenesis, and tissue response. Clinical outcomes for TB-500.
Human evidence

Human data

A randomized single- and multiple-dose study evaluated intravenous full-length thymosin beta-4 in healthy volunteers, and a later first-in-human study evaluated recombinant human Tβ4. A phase 2 venous-ulcer study evaluated topical full-length Tβ4. These are not direct trials of a separately defined TB-500 fragment. No adequate controlled human evidence for the exact TB-500 material represented here was identified.

Preclinical evidence

Animal data

Full-length Tβ4 preclinical studies examine cell migration, angiogenesis, inflammation, and tissue injury. Fragment activity depends on the retained sequence and conformation, so parent-peptide results cannot be assumed to apply.

Laboratory evidence

In-vitro and analytical context

Actin binding and cell-migration assays are prominent in Tβ4 research. Any TB-500 experiment should publish exact sequence, purity, counterion, aggregation state, and a direct comparison with full-length Tβ4.

Research limitations

  • Commercial naming does not consistently define the molecular sequence.
  • Most cited human evidence concerns full-length Tβ4, not TB-500.
  • Parent-peptide findings cannot be transferred automatically to a fragment.
  • Human pharmacokinetics, safety, and efficacy for exact TB-500 remain unresolved.

Future research

The priority is an unambiguous molecular definition followed by validated identity and purity testing, direct head-to-head pharmacology with full-length Tβ4, toxicology, pharmacokinetics, and only then controlled human research.

Primary references

  1. Ruff D, et al. Randomized single- and multiple-dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. doi:10.1111/j.1749-6632.2010.05474.x.
  2. Wang X, et al. First-in-human study of recombinant human thymosin beta4. J Cell Mol Med. 2021. doi:10.1111/jcmm.16693.
  3. Guarnera G, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010. doi:10.1111/j.1749-6632.2010.05490.x.

Article record

Research question
What does the published evidence on TB-500 show across human, animal, and laboratory research?
Evidence cutoff
July 15, 2026
Article status
Published educational research summary; not independently peer reviewed
Author
JD BioWorks Research Library
Editorial review
JD BioWorks Research Library
Planned review cycle
At least annually, or sooner if material evidence or regulatory information changes

This article summarizes published research for educational and laboratory-information purposes. It is not medical advice, does not provide instructions for personal use, and does not establish that any material is safe or effective for human or veterinary use.

Connected Materials

No associated research material is currently listed.Relationships can be added from the Related Compounds panel.

CONTINUE YOUR REVIEW

Next steps for qualified researchers

Use the public documentation resources below, then continue to Research Product Access when you are ready to review the gated catalog.

Search Certificates of Analysis Match available analytical records to the named product, quantity, and lot. Explore Research Guides Review HPLC, LC-MS, purity, identity, storage, and traceability guidance. Get Research Product Access Complete the Research Use Acknowledgment to create an account and receive automatic product access.

For qualified laboratory, analytical, educational, or institutional research only. Not for human or veterinary use.